Flavaglines: Potent anticancer drugs that target prohibitins and the helicase eIF4A

Future Medicinal Chemistry

Volumn 5, Issue 18, 2013, Pages 2185-2197

  Basmadjian, Christine ^a   Thuaud, Frédéric ^a   Ribeiro, Nigel ^a   Désaubry, Laurent ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYFLAVONE DERIVATIVE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBAISOSTERE; DOXORUBICIN; FLAVAGLINE DERIVATIVE; HELICASE; INITIATION FACTOR; INITIATION FACTOR 4A; PROHIBITIN; SCAFFOLD PROTEIN; THIOREDOXIN INTERACTING PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; AGLAIA; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOMIMETICS; CANCER CELL; CELL PROTECTION; CELL SURVIVAL; CLINICAL STUDY; CYCLIZATION; CYTOTOXICITY; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG SYNTHESIS; DRUG TARGETING; ENANTIOSELECTIVITY; HEART PROTECTION; HEMATOPOIETIC CELL; HUMAN; MEDICINAL PLANT; MULTIDRUG RESISTANCE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SOUTHEAST ASIA; STRUCTURE ACTIVITY RELATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; EUKARYOTIC INITIATION FACTOR-4A; HUMANS; REPRESSOR PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84889576947     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.177     Document Type: Review

References (55)

1. Baumann B, Bohnenstengel F, Siegmund D et al. Rocaglamide derivatives are potent inhibitors of NF-kB activation in T-cells. J. Biol. Chem. 277(47), 44791-44800 (2002). (Pubitemid 36159073)
2. King ML, Chiang CC, Ling HC, Fujita E, Ochiai M, McPhail AT. x-ray crystal structure of rocaglamide, a novel antileukemic 1H-cyclopenta[b] benzofuran from Aglaia elliptifolia. Chem. Commun. 20(1982), 1150-1151 (1992).
3. Ebada SS, Lajkiewicz N, Porco JA Jr, Li- Weber M, Proksch P. Chemistry and biology of rocaglamides (= flavaglines) and related derivatives from Aglaia species (Meliaceae). Prog. Chem. Org. Nat. Prod. 94, 1-58 (2011).
4. Ribeiro N, Thuaud F, Nebigil C, Dsaubry L. Recent advances in the biology and chemistry of the flavaglines. Bioorg. Med. Chem. 20(6), 1857-1864 (2012).
5. Lindqvist LM, Vikstrom I, Chambers JM et al. Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. Cell. Death. Dis. 3, e409 (2012).
6. Proksch P, Giaisi M, Treiber MK et al. Rocaglamide derivatives are immunosuppressive phytochemicals that target NF-AT activity in T cells. J. Immunol, 174(11), 7075-7084 (2005). (Pubitemid 40705673)
7. Zhu JY, Giaisi M, Kohler R et al. Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression. Cell Death Differ. 16(9), 1289-1299 (2009).
8. Zhu JY, Lavrik IN, Mahlknecht U et al. The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen-activated protein kinase activities. Int. J. Cancer 121(8), 1839-1846 (2007). (Pubitemid 47417305)
9. Kim S, Salim AA, Swanson SM, Kinghorn AD. Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anticancer. Agents Med. Chem. 6(4), 319-345 (2006). (Pubitemid 44027699)
10. Proksch P, Edrada R, Ebel R, Bohnenstengel F, Nugroho B. Chemistry and biological activity of rocaglamide derivatives and related compounds in Aglaia species (Meliaceae). Curr. Org. Chem. 5, 923-938 (2001). (Pubitemid 33069422)
11. Trost BM, Greenspan PD, Yang BV, Saulnier MG. An unusual oxidative cyclization. A synthesis and absolute stereochemical assignment of (-)-rocoglamide. J. Am. Chem. Soc. 112(24), 9022-9024 (1990).
12. Malona JA, Cariou K, Spencer WT III, Frontier AJ. Total synthesis of ()-rocaglamide via oxidation-initiated nazarov cyclization. J. Org. Chem. 77(4), 1891-1908 (2012).
13. Magnus P, Freund WA, Moorhead EJ, Rainey T. Formal synthesis of ()-methyl rocaglate using an unprecedented acetyl bromide mediated nazarov reaction. J. Am. Chem. Soc. 134(14), 6140-6142 (2012).
14. Lajkiewicz NJ, Roche SP, Gerard B, Porco JA. Enantioselective photocycloaddition of 3-hydroxyflavones: total syntheses and absolute configuration assignments of (+)-ponapensin and (+)-elliptifoline. J. Am. Chem. Soc. 134(31), 13108-13113 (2012).
15. Liu T, Nair SJ, Lescarbeau A et al. Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors. J. Med. Chem. 55(20), 8859-8878 (2012).
16. Polier G, Neumann J, Thuaud F et al. The natural anticancer compounds rocaglamides inhibit the RAF-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem. Biol. 19(9), 1093-1104 (2012).
17. Thuaud F, Ribeiro N, Nebigil CG, Dsaubry L. Prohibitin ligands in cell death and survival: mode of action and therapeutic potential. Chem. Biol. 20(3), 316-331 (2013).
18. Matallanas D, Birtwistle M, Romano D et al. RAF family kinases: old dogs have learned new tricks. Genes Cancer 2(3), 232-260 (2011).
19. Bordeleau ME, Robert F, Gerard B et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J. Clin. Invest. 118(7), 2651-2660 (2008). (Pubitemid 351949792)
20. Cencic R, Carrier M, Galicia-Vazquez G et al. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS ONE 4(4), e5223 (2009).
21. Nasr Z, Robert F, Porco JA Jr., Muller WJ, Pelletier J. eIF4F suppression in breast cancer affects maintenance and progression. Oncogene 32(7), 861-871 (2012).
22. Schatz JH, Oricchio E, Wolfe AL et al. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J. Exp. Med. 208(9), 1799-1807 (2011).
23. Jin C, Rajabi H, Rodrigo CM, Porco JA Jr., Kufe D. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene 32(17), 2179-2188 (2012).
24. Alinari L, Prince CJ, Edwards RB et al. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol. Clin. Cancer Res. 18(17), 4600-4611 (2012).
25. Lucas DM, Edwards RB, Lozanski G et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 113(19), 4656-4666 (2009).
26. Chambers JM, Lindqvist LM, Webb A, Huang DCS, Savage GP, Rizzacasa MA. Synthesis of biotinylated Episilvestrol: highly selective targeting of the translation factors eIF4AI/II. Org. Lett. 15(6), 1406-1409 (2013).
27. Sadlish H, Galicia-Vazquez G, Paris CG et al. Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA Complex. ACS Chem. Biol. 8 (7), 1519-1527 (2013).
28. Santagata S, Mendillo ML, Tang YC et al. Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science 341(6143), 1238303 (2013).
29. Ruggero D. Translational control in cancer etiology. Cold Spring Harb. Perspect. Biol. 5(2) (2013).
30. Guo F, Hiroshima K, Wu D et al. Prohibitin and its rapidly emerging role as a biomarker of systemic malignancies-reply. Hum. Pathol. 44(4), 679-680 (2013).
31. Kapoor S. Prohibitin and its rapidly emerging role as a biomarker of systemic malignancies. Hum. Pathol. 44(4), 678-679 (2013).
32. Barnhart KF, Christianson DR, Hanley PW et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci. Transl. Med. 3(108), 108ra112 (2011).
33. Mi Q, Su BN, Chai H et al. Rocaglaol induces apoptosis and cell cycle arrest in LNCaP cells. Anticancer Res. 26(2A), 947-952 (2006).
34. Thuaud F, Bernard Y, Turkeri G et al. Synthetic analogue of Rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and Caspase-12. J. Med Chem, 52(16), 5176-5187 (2009).
35. Lee SK, Cui B, Mehta RR, Kinghorn AD, Pezzuto JM. Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from Aglaia elliptica. Chem. Biol. Interact. 115(3), 215-228 (1998). (Pubitemid 28487025)
36. Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat. Rev. Clin. Oncol. 6(5), 259-265 (2009).
37. Rodrigo CM, Cencic R, Roche SP, Pelletier J, Porco JA. Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies. J. Med. Chem., 55(1), 558-562 (2012).
38. Liu T, Nair SJ, Lescarbeau A et al. Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors. J. Med. Chem. 55(20), 8859-8878 (2012).
39. Hwang BY, Su BN, Chai H et al. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J. Org. Chem. 69(10), 3350-3358 (2004). (Pubitemid 38621283)
40. Alachkar H, Santhanam R, Harb JG et al. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. J. Hematol. Oncol. 6, 21 (2013).
41. Gupta SV, Sass EJ, Davis ME et al. Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. AAPS J. 13(3), 357-364 (2011).
42. Thuaud F, Ribeiro N, Gaiddon C, Cresteil T, Dsaubry L. Novel flavaglines displaying improved cytotoxicity. J. Med. Chem. 54, 411-415 (2011).
43. Ribeiro N, Thuaud F, Bernard Y et al. Flavaglines as potent anticancer and cytoprotective agents. J. Med. Chem. 55, 10064-10073 (2012).
44. Fahrig T, Gerlach I, Horvath E. A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury. Mol. Pharmacol. 67(5), 1544-1555 (2005). (Pubitemid 40594153)
45. Lucas CR, Cordero-Nieves HM, Erbe RS et al. Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes. J. Immunol. 190(2), 723-736 (2013).
46. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56(2), 185-229 (2004). (Pubitemid 38720829)
47. Bernard Y, Ribeiro N, Thuaud F et al. Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27. PLoS ONE 6, e25302 (2011).
48. Kostenko S, Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell. Mol. Life Sci. 66, 3289-3307 (2009).
49. Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J. Biol. Chem. 278(48), 47853-47861 (2003). (Pubitemid 37523233)
50. Di Marco S, Cammas A, Lian XJ et al. The translation inhibitor pateamine A prevents cachexia-induced muscle wasting in mice. Nat. Commun. 3, 896 (2012).
51. Lindqvist L, Pelletier J. Inhibitors of translation initiation as cancer therapeutics. Future Med. Chem. 1(9), 1709-1722 (2009).
52. Romo D, Choi NS, Li S, Buchler I, Shi Z, Liu JO. Evidence for separate binding and scaffolding domains in the immunosuppressive and antitumor marine natural product, pateamine a: design, synthesis, and activity studies leading to a potent simplified derivative. J. Am. Chem. Soc. 126(34), 10582-10588 (2004). (Pubitemid 39129157)
53. Baiocchi RA, Patton JT Jr, Lucas DM, Kinghorn D, Grever M: WO2013016658 (2013).
54. Wabnitz P, Gehling M, Henkel T, Schmitz ML: WO2010063471 A1 (2010).
55. IMD-026259: an innovative drug for disease-modifying treatment of Parkinson's disease. www.michaeljfox.org/foundation/grant-detail.php?grant-id= 1020